ReviewFrontiers in oncology2022
Neoadjuvant Therapy for Locally Advanced Esophageal Cancers.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Prevalence of sarcopenia in esophageal cancer patients receiving preoperative neoadjuvant therapy: a systematic review and meta-analysis.International journal of clinical oncology · 2026Pooled it
- Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29).Esophagus : official journal of the Japan Esophageal Society · 2026Trial
- Article
- Association between tumor volume changes during neoadjuvant chemoimmunotherapy and survival outcomes in esophageal squamous cell carcinoma: a multicenter study.Frontiers in immunology · 2026Article
- The enhanced pathological response from additional immunotherapy improved recurrence-free survival for esophageal squamous cell carcinoma: a multi-center cohort study.Surgical endoscopy · 2025Article
- Gender, racial, and socioeconomic disparities in the management and survival of patients with locally advanced esophageal cancer: a SEER-based study.Surgical endoscopy · 2025Article
- Complete remission of unresectable advanced esophageal squamous cell carcinoma following nivolumab immunotherapy after chemoradiotherapy: a case report.International cancer conference journal · 2025Article
- Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Translational cancer research · 2025Article
- The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study.Frontiers in immunology · 2025Article
- Evolving Therapeutic Strategies in Esophageal Squamous Cell Carcinoma: Advances and Perspectives.Journal of cancer prevention · 2024Review
- Targeting Radiation Resistance in Oesophageal Adenocarcinoma with Pyrazinib-Functionalised Gold Nanoparticles.Cancers · 2024Article
- Clinical and genetic characteristics of patients with TRG 0 and TRG III in esophageal squamous cell carcinoma after neoadjuvant therapy.Scientific reports · 2024Article
- The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas.Cancers · 2023Review
- Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.Biomedicines · 2023Review
- Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.World journal of surgical oncology · 2023Article
- The application of radiomics in esophageal cancer: Predicting the response after neoadjuvant therapy.Frontiers in oncology · 2023Review
- Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regimen, radiation dose, and surgical intervals are uncertain and the rate of recurrence after neoadjuvant therapy is high. Patients receiving neoadjuvant therapy and reaching a pathological complete response have been reported to have a better survival benefit and a fewer recurrence risk than those non-pathological complete responses. Nevertheless, less than half of patients will reach a pathological complete response after neoadjuvant therapy, and the methods to evaluate the efficacy after neoadjuvant therapy accurately are limited. Immune checkpoint inhibitors have been recommended for the treatments of advanced esophageal cancers. Recently, research has been beginning to evaluate the safety and efficacy of immunotherapy combined with neoadjuvant therapy. Here, we will review and discuss the development of the neoadjuvant therapy of locally advanced esophageal cancers and unsolved clinical problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.